Bli medlem
Bli medlem

Du är här

2014-05-26

AstraZeneca: Statement regarding Pfizer withdrawal

AstraZeneca PLC ("AstraZeneca") notes the announcement made by Pfizer
Inc. ("Pfizer") that, in accordance with the requirements of the UK
City Code on Takeovers and Mergers (the "Takeover Code"), Pfizer does
not intend to make an offer for AstraZeneca. Accordingly, Pfizer is
bound by the restrictions of the Takeover Code.

Leif Johansson, Chairman of AstraZeneca, said: "We note Pfizer's
confirmation that it no longer intends to make an offer for
AstraZeneca. We welcome the opportunity to continue building on the
momentum we have already demonstrated as an independent company.

We are fully focused on the delivery of our strategy. We have
attractive growth prospects and a rapidly progressing pipeline. In
the coming months, we anticipate positive news flow across our core
therapeutic areas, which underpins our confidence in the long-term
prospects of the business.

The Board is grateful to Pascal, his management team and to all our
employees for their dedication and focus over a period of
uncertainty. AstraZeneca has a culture of innovation, with science at
the heart of everything we do. I believe this will create significant
value for our shareholders, employees and patients who will benefit
from our life-changing medicines."

A copy of this announcement will be available on AstraZeneca's website
at www.astrazeneca.com.

- ENDS -

NOTES TO EDITORS

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of
cardiovascular, metabolic, respiratory, inflammation, autoimmune,
oncology, infection and neuroscience diseases. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:
www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)

Ayesha Bharmal +44 20 7604 8034 (UK/Global)

Jacob Lund +46 8 553 260 20 (Sweden)

Investor Enquiries

Karl Hård +44 20 7604 8123  mob: +44 7789 654364

Adviser Enquiries

Robey Warshaw: Simon Robey +44 20 7317 3900

Simon Warshaw

Evercore Partners: Francois Maisonrouge +1 212 857 3100

Goldman Sachs: Karen Cook +44 20 7774 1000

Phil Raper (Corporate Broking)

Morgan Stanley: Colm Donlon +44 20 7425 8000

Andrew Foster (Corporate Broking)

RLM Finsbury: Conor McClafferty +44 20 7251 3801

Further Information

Robey Warshaw LLP, which is authorised and regulated in the United
Kingdom by the Financial Conduct Authority, is acting as financial
adviser exclusively for AstraZeneca and no one else in connection
with the matters referred to in this announcement and will not regard
any other person as its client in relation to the matters referred to
in this announcement and will not be responsible to anyone other than
AstraZeneca for providing the protections afforded to clients of
Robey Warshaw LLP, nor for providing advice in relation to the
matters referred to in this announcement.

Evercore Partners International LLP, which is authorised and regulated
in the United Kingdom by the Financial Conduct Authority, is acting
as financial adviser exclusively for AstraZeneca and no one else in
connection with the matters referred to in this announcement and will
not regard any other person as its client in relation to the matters
referred to in this announcement and will not be responsible to
anyone other than AstraZeneca for providing the protections afforded
to clients of Evercore Partners International LLP, nor for providing
advice in relation to the matters referred to in this announcement.

Goldman Sachs International, which is authorised by the Prudential
Regulation Authority and regulated by the Financial Conduct Authority
and the Prudential Regulation Authority in the United Kingdom, is
acting exclusively for AstraZeneca and no one else in connection with
the matters referred to in this announcement and will not be
responsible to anyone other than AstraZeneca for providing the
protections afforded to clients of Goldman Sachs International, or
for providing advice in connection with the matters referred to in
this announcement.

Morgan Stanley & Co. International plc, which is authorised by the
Prudential Regulation Authority and regulated by the Financial
Conduct Authority and the Prudential Regulation Authority in the
United Kingdom, is acting as financial adviser to AstraZeneca, and no
one else in connection with the matters referred to in this
announcement. In connection with such matters, Morgan Stanley & Co.
International plc, its affiliates and its and their respective
directors, officers, employees and agents will not regard any other
person as their client, nor will they be responsible to any other
person other than AstraZeneca for providing the protections afforded
to their clients or for providing advice in connection with the
contents of this announcement or any other matter referred to herein.

Forward-Looking Statements

This announcement (including information incorporated by reference in
this announcement), oral statements made regarding the Proposal, and
other information published by AstraZeneca contain statements which
are, or may be deemed to be, "forward-looking statements", including
for the purposes of the US Private Securities Litigation Reform Act
of 1995. Forward-looking statements are prospective in nature and are
not based on historical facts, but rather on current expectations and
projections of the management of AstraZeneca about future events, and
are therefore subject to risks and uncertainties which could cause
actual results to differ materially from the future results expressed
or implied by the forward-looking statements. Often, but not always,
forward-looking statements can be identified by the use of
forward-looking words such as "plans", "expects" or "does not
expect", "is expected", "is subject to", "budget", "scheduled",
"estimates", "forecasts", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or statements that certain actions, events or results "may", "could",
"should", "would", "might" or "will" be taken, occur or be achieved.
Although AstraZeneca believes that the expectations reflected in such
forward-looking statements are reasonable, AstraZeneca can give no
assurance that such expectations will prove to be correct. By their
nature, forward-looking statements involve risk and uncertainty
because they relate to events and depend on circumstances that will
occur in the future. There are a number of factors that could cause
actual results and developments to differ materially from those
expressed or implied by such forward-looking statements. These
factors include the loss or expiration of patents, marketing
exclusivity or trademarks, or the risk of failure to obtain patent
protection; the risk of substantial adverse litigation/government
investigation claims and insufficient insurance coverage; exchange
rate fluctuations; the risk that R&D will not yield new products that
achieve commercial success; the risk that strategic alliances and
acquisitions will be unsuccessful; the impact of competition, price
controls and price reductions; taxation risks; the risk of
substantial product liability claims; the impact of any delays in the
manufacturing, distribution and sale of any of AstraZeneca's
products; the impact of any failure by third parties to supply
materials or services; the risk of failure to manage a crisis; the
risk of delay to new product launches; the difficulties of obtaining
and maintaining regulatory approvals for products; the risk of
failure to observe ongoing regulatory oversight; the risk that new
products do not perform as AstraZeneca expects; the risk of
environmental liabilities; the risks associated with conducting
business in emerging markets; the risk of reputational damage; the
risk of product counterfeiting; the risk of failure to successfully
implement planned cost reduction measures through productivity
initiatives and restructuring programmes; the risk that regulatory
approval processes for biosimilars could have an adverse effect on
future commercial prospects; the impact of failing to attract and
retain key personnel and to successfully engage with AstraZeneca's
employees; and the impact of increasing implementation and
enforcement of more stringent anti-bribery and anti-corruption
legislation. Other unknown or unpredictable factors could cause
actual results to differ materially from those in the forward-looking
statements. Such forward-looking statements should therefore be
construed in the light of such factors. Neither AstraZeneca nor any
of its associates or directors, officers or advisers, provides any
representation, assurance or guarantee that the occurrence of the
events expressed or implied in any forward-looking statements in this
announcement will actually occur. You are cautioned not to place
undue reliance on these forward-looking statements. Other than in
accordance with its legal or regulatory obligations, AstraZeneca is
not under any obligation, and AstraZeneca expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

-----------------------------------------------------------
http://news.cision.com/se/astrazeneca/r/statement-regarding-pfizer-withd...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.